Antipsychotic drugs and hyperglycemia in older patients with diabetes

Archives of Internal Medicine

Volumn 169, Issue 14, 2009, Pages 1282-1289

  Lipscombe, Lorraine L ^a,b,e   Lévesque, Linda ^a,d   Gruneir, Andrea ^e   Fischer, Hadas D ^a   Juurlink, David N ^a,b,c,f   Gill, Sudeep S ^a,d   Herrmann, Nathan ^f   Hux, Janet E ^a,b,c,f   Anderson, Geoff M ^a,c   Rochon, Paula A ^a,b,c,e  

^a INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d QUEEN S UNIVERSITY   (Canada)

^e WOMEN S COLLEGE HOSPITAL   (Canada)

^f SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMIODARONE; ATYPICAL ANTIPSYCHOTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUSPIRONE; CIMETIDINE; CORTICOSTEROID; CYTOCHROME P450 2C9; ENZYME INHIBITOR; FIBRIC ACID DERIVATIVE; FLUCONAZOLE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LITHIUM CARBONATE; LOSARTAN; METOCLOPRAMIDE; NEUROLEPTIC AGENT; NICOTINIC ACID; OLANZAPINE; ORAL ANTIDIABETIC AGENT; PHENYTOIN; PROTEINASE INHIBITOR; QUETIAPINE; QUINIDINE SULFATE; RIFAMPICIN; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; TACROLIMUS; THIAZIDE DIURETIC AGENT; VALPROIC ACID;

AGED; ARTICLE; CANADA; CASE CONTROL STUDY; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DATA BASE; DEMENTIA; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE DURATION; EMERGENCY WARD; GERIATRIC PATIENT; HEALTH CARE UTILIZATION; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; HYPERGLYCEMIA; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RISK ASSESSMENT; SCHIZOPHRENIA;

AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; CASE-CONTROL STUDIES; COHORT STUDIES; DIABETES COMPLICATIONS; FEMALE; HOSPITALIZATION; HUMANS; HYPERGLYCEMIA; MALE;

EID: 67749130825     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinternmed.2009.207     Document Type: Article

References (35)

1. Snowdon J, Day S, Baker W. Why and how antipsychotic drugs are used in 40 Sydney nursing homes. Int J Geriatr Psychiatry. 2005;20(12):1146-1152.
2. Rapoport M, Mamdani M, Shulman KI, Herrmann N, Rochon PA. Antipsychotic use in the elderly: shifting trends and increasing costs. Int J Geriatr Psychiatry. 2005;20(8):749-753.
3. Valiyeva E, Herrmann N, Rochon PA, Gill SS, Anderson GM. Effect of regulatory warnings on antipsychotic prescription rates among elderly patients with dementia: a population-based time-series analysis. CMAJ. 2008;179(5):438-446.
4. Gill SS, Rochon PA, Herrmann N, et al. Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study. BMJ. 2005;330(7489):445.
5. Gill SS, Bronskill SE, Normand SL, et al. Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med. 2007;146(11):775-786.
6. Rochon PA, Normand SL, Gomes T, et al. Antipsychotic therapy and short-term serious events in older adults with dementia. Arch Intern Med. 2008;168(10):1090-1096.
7. Allison DB, Casey DE. Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry. 2001;62(suppl 7):22-31.
8. Muench J, Carey M. Diabetes mellitus associated with atypical antipsychotic medications: new case report and review of the literature. J Am Board Fam Pract. 2001;14(4):278-282.
9. Roefaro J, Mukherjee SM. Olanzapine-lnduced hyperglycemic nonketonic coma. Ann Pharmacother. 2001;35(3):300-302.
10. Takahashi M, Ohishi S, Katsumi C, Moriya T, Miyaoka H. Rapid onset of quetiapine-induced diabetic ketoacidosis in an elderly patient: a case report. Pharmacopsychiatry. 2005;38(4):183-184.
11. Lipscombe LL, Hux JE. Trends in diabetes prevalence, incidence, and mortality in Ontario, Canada 1995-2005: a population-based study. Lancet. 2007;369(9563):750-756.
12. Gianfrancesco F, Pesa J, Wang RH, Nasrallah H. Assessment of antipsychotic-related risk of diabetes mellitus in a Medicaid psychosis population: sensitivity to study design. Am J Health Syst Pharm. 2006;63(5):431-441.
13. Ramaswamy K, Masand PS, Nasrallah HA. Do certain atypical antipsychotics increase the risk of diabetes? a critical review of 17 pharmacoepidemiologic studies. Ann Clin Psychiatry. 2006;18(3):183-194.
14. Smith M, Hopkins D, Peveler RC, Holt RI, Woodward M, Ismail K. First- v. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis. Br J Psychiatry. 2008;192(6):406-411.
15. Schneider LS, Tariot PN, Dagerman KS, et al; CATIE-AD Study Group. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med. 2006;355(15):1525-1538.
16. Etminan M, Streiner DL, Rochon PA. Exploring the association between atypical neuroleptic agents and diabetes mellitus in older adults. Pharmacotherapy. 2003;23(11):1411-1415.
17. Rondanelli M, Sarra S, Antoniello N, et al. No effect of atypical antipsychotic drugs on weight gain and risk of developing type II diabetes or lipid abnormalities among nursing home elderly patients with Alzheimer's disease. Minerva Med. 2006;97(2):147-151.
18. Micca JL, Hoffmann VP, Lipkovich I, Ahl J, Baker RW, Hardy TA. Retrospective analysis of diabetes risk in elderly patients with dementia in olanzapine clinical trials. Am J Geriatr Psychiatry. 2006;14(1):62-70.
19. Feldman PD, Hay LK, Deberdt W, et al. Retrospective cohort study of diabetes mellitus and antipsychotic treatment in a geriatric population in the United States. J Am Med Dir Assoc. 2004;5(1):38-46.
20. Thonnard-Neumann E. Phenothiazines and diabetes in hospitalized women. Am J Psychiatry. 1968;124(7):978-982.
21. Hiles BW. Hyperglycemia and glycosuria following chlorpromazine therapy. JAMA. 1956;162(18):1651.
22. Levy AR, O'Brien BJ, Sellors C, Grootendorst P, Willison D. Coding accuracy of administrative drug claims in the Ontario Drug Benefit database. Can J Clin Pharmacol. 2003;10(2):67-71.
23. Hux JE, Ivis F, Flintoft V, Bica A. Diabetes in Ontario: determination of prevalence and incidence using a validated administrative data algorithm. Diabetes Care. 2002;25(3):512-516.
24. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613-619.
25. Suissa S. Novel approaches to pharmacoepidemiology study design and statistical analysis. In: Strom BL, ed. Pharmacoepidemiology. 4th ed. Chichester, England: John Wiley & Sons Ltd; 2005:811-829.
26. Essebag V, Platt RW, Abrahamowicz M, Pilote L. Comparison of nested case-control and survival analysis methodologies for analysis of time-dependent exposure. BMC Med Res Methodol. 2005;5(1):5.
27. Donihi AC, Raval D, Saul M, Korytkowski MT, DeVita MA. Prevalence and predictors of corticosteroid-related hyperglycemia in hospitalized patients. Endocr Pract. 2006;12(4):358-362.
28. Dixon L, Weiden P, Delahanty J, et al. Prevalence and correlates of diabetes in national schizophrenia samples. Schizophr Bull. 2000;26(4):903-912.
29. Holt RI, Peveler RC. Antipsychotic drugs and diabetes - an application of the Austin Bradford Hill criteria. Diabetologia. 2006;49(7):1467-1476.
30. Moride Y, Abenhaim L, Yola M, Lucein A. Evidence of the depletion of susceptibles effect in non-experimental pharmacoepidemiologic research. J Clin Epidemiol. 1994;47(7):731-737.
31. Holt RI, Peveler RC. Association between antipsychotic drugs and diabetes. Diabetes Obes Metab. 2006;8(2):125-135.
32. Bina KG, Cincotta AH. Dopaminergic agonists normalize elevated hypothalamic neuropeptide Y and corticotropin-releasing hormone, body weight gain, and hyperglycemia in ob/ob mice. Neuroendocrinology. 2000;71(1):68-78.
33. Scranton RE, Gaziano JM, Rutty D, Ezrokhi M, Cincotta A. A randomized, double-blind, placebo-controlled trial to assess safety and tolerability during treatment of type 2 diabetes with usual diabetes therapy and either Cycloset or placebo. BMC Endocr Disord. 2007;7:3.
34. Sinclair AJ, Girling AJ, Bayer AJ. Cognitive dysfunction in older subjects with diabetes mellitus: impact on diabetes self-management and use of care services: All Wales Research into Elderly (AWARE) Study. Diabetes Res Clin Pract. 2000;50(3):203-212.
35. Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P. Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol. 2006;5(1):64-74.